We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Santhera Pharmaceuticals has announced an exclusive license agreement with BioLineRx, covering Santhera's pre-clinical melanocortin-4 receptor (MC-4R) antagonist program currently in development for the treatment of cancer cachexia.

Under the agreement, BioLineRx acquires all rights to develop, sub-license and commercialize the compound. BioLineRx will cover all future costs of the program. Santhera will receive 22% to 25% of all BioLineRx's sub-licensing income or royalties on future sales by BioLineRx. The out-licensing deal is in line with Santhera's strategy to focus on its core late stage or marketed assets: Catena®, fipamezole and omigapil.

The preclinical activity spectrum of orally active MC-4R antagonists indicates beneficial efficacy in all key aspects of cachexia such as lack of appetite, increased resting energy expenditure and enhanced catabolism. The latest generation of compounds increased food intake 3- to 5-fold and inhibited the development of cachexia in a disease-relevant animal tumor model.

"We received considerable interest in this program and concluded that BioLineRx is the best partner for development of our selective, first-in-class MC-4R antagonists based on their excellent track record in developing similar stage assets to proof-of-concept in man," said Klaus Schollmeier, Chief Executive Officer of Santhera. "This agreement with BioLineRx fits well with Santhera's strategy to focus on its core late stage or marketed assets Catena®, fipamezole and omigapil."
Advertisement